A carregar...
Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
Na minha lista:
| Publicado no: | Int J Infect Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883703/ https://ncbi.nlm.nih.gov/pubmed/33601033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2021.02.035 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|